Table 1.

Demographics and Results of RCB data for the 34 subjects enrolled on study, received NACT, and had data from their 2-week DOT evaluation

Characteristic
Age (mean ± SD)	49.9 years ± 11.3
BMI (mean ± SD)	30 ± 6.2
Tumor histologic subtype
Invasive ductal carcinoma (n, %)	30 (88%)
Invasive lobular carcinoma (n, %)	4 (12%)
Hormone/HER2 status
HR+/HER2− (n, %)	17 (50%)
HR+/HER2+ (n, %)	9 (26.5%)
HR−/HER2+ (n, %)	3 (8.8%)
HR−/HER2− (n, %)	5 (14.7%)
RCB class
RCB 0 (n, %)	13 (38.2%)
RCB 1 (n, %)	2 (5.9%)
RCB 2 (n, %)	13 (38.2%)
RCB 3 (n, %)	6 (17.6%)

BMI body mass index, HR hormone receptor; estrogen and progesterone receptor staining >1% of cells was classified as HR positive, HER2 human epidermal growth factor receptor 2, RCB residual cancer burden